Avanos Medical Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Avanos Medical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVNS, but not buy additional shares or sell existing shares.
View analyst ratings for Avanos Medical or view top-rated stocks.

Wall Street analysts have given Avanos Medical a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avanos Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Avanos Medical is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Avanos Medical.

Avanos Medical, Inc. (NYSE:AVNS) released its quarterly earnings data on Monday, August, 2nd. The company reported $0.21 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.23 by $0.02. The business earned $186.40 million during the quarter, compared to analyst estimates of $180.56 million. Avanos Medical had a net margin of 0.33% and a trailing twelve-month return on equity of 3.52%. The firm's revenue for the quarter was up 13.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.13 earnings per share.
View Avanos Medical's earnings history.

Avanos Medical's stock was trading at $29.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AVNS shares have increased by 12.0% and is now trading at $32.49.
View which stocks have been most impacted by COVID-19.

Avanos Medical issued an update on its FY 2021 earnings guidance on Tuesday, August, 10th. The company provided earnings per share (EPS) guidance of $1.100-$1.200 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.210. The company issued revenue guidance of $729.10 million-$743.39 million, compared to the consensus revenue estimate of $741.22 million.

3 equities research analysts have issued 12 month target prices for Avanos Medical's stock. Their forecasts range from $41.00 to $47.00. On average, they anticipate Avanos Medical's share price to reach $44.33 in the next twelve months. This suggests a possible upside of 36.5% from the stock's current price.
View analysts' price targets for Avanos Medical or view top-rated stocks among Wall Street analysts.

32 employees have rated Avanos Medical CEO Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among Avanos Medical's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Avanos Medical include MSA Safety (MSA), Establishment Labs (ESTA), Inogen (INGN), Eargo (EAR), D8 (DEH), Sientra (SIEN), Conformis (CFMS), Sanara MedTech (SMTI), United Health Products (UEEC), Invacare (IVC), Lakeland Industries (LAKE), Surgalign (SRGA), Milestone Scientific (MLSS), Alpha Pro Tech (APT) and CollPlant Biotechnologies (CLGN).
View all of AVNS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Honeywell International (HON), Pfizer (PFE), The Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Avanos Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.32%), Vanguard Group Inc. (10.59%), Champlain Investment Partners LLC (5.42%), Price T Rowe Associates Inc. MD (5.14%), Dimensional Fund Advisors LP (4.95%) and RGM Capital LLC (4.48%). Company insiders that own Avanos Medical stock include Gary Blackford and Patrick J Oleary.
View institutional ownership trends for Avanos Medical.

AVNS stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Price T Rowe Associates Inc. MD, Champlain Investment Partners LLC, JPMorgan Chase & Co., Northern Trust Corp, Tygh Capital Management Inc., William Blair Investment Management LLC, and Employees Retirement System of Texas.
View insider buying and selling activity for Avanos Medical or view top insider-selling stocks.

AVNS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Morgan Stanley, Morgan Stanley, Nuveen Asset Management LLC, RGM Capital LLC, Principal Financial Group Inc., and Macquarie Group Ltd.. Company insiders that have bought Avanos Medical stock in the last two years include Gary Blackford, and Patrick J Oleary.
View insider buying and selling activity for Avanos Medical or or view top insider-buying stocks.

Shares of AVNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVNS stock can currently be purchased for approximately $32.49.

Avanos Medical has a market capitalization of $1.56 billion and generates $714.80 million in revenue each year. The company earns $-27,200,000.00 in net income (profit) each year or $0.79 on an earnings per share basis.

Avanos Medical employs 5,300 workers across the globe.

The official website for Avanos Medical is avanos.com.

Avanos Medical is headquartered at 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004.

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The company can be reached via phone at (844) 428-2667 or via email at [email protected]